Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials
Abstract The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease (COVID-19) is disputed. This systematic review and meta-analysis aimed to examine the efficacy and safety of HCQ in addition to standard of care (SOC) in COVID-19. PubMed, the Cochrane Library, Embase, Web o...
Enregistré dans:
Auteurs principaux: | Bahman Amani, Ahmad Khanijahani, Behnam Amani |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3fae3b80e5fa43b392327e3396b82de0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
par: Behnam Amani, et autres
Publié: (2021) -
A Standard of Care
par: Peter M. Bingham
Publié: (2017) -
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
par: Cathrine Axfors, et autres
Publié: (2021) -
Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
par: Timothée Olivier, et autres
Publié: (2022) -
Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial.
par: Ole Jakob Storebø, et autres
Publié: (2012)